

**From:** [Giordano, Erica](#)  
**To:** [Patel, Manisha \(manisha.patel@novartis.com\)](#)  
**Cc:** [Riggins, Cindy](#); [narin.ahmed@novartis.com](#)  
**Subject:** BL 125646 CMC Information Request  
**Date:** Thursday, July 13, 2017 12:26:59 PM  
**Attachments:** [image001.png](#)

---

Good afternoon,

Please see the information request below and provide a response by 4 pm tomorrow, July 14, 2017. As usual please provide a response directly to this e-mail and follow-up by submitting the information as an amendment to the BLA.

Please provide the missing information for the deviation (page 143, deviation # 1738942) in the document entitled "PVR5135-22A: PPQ Addendum Report for pALL CTL019 Product" in amendment #32 (Series #31) submitted on June 16, 2017.

Please confirm receipt of this request.

*Thank you,*

**Erica Giordano**

*Regulatory Project Manager*

Center for Biologics Evaluation and Research

Office of Tissues and Advanced Therapies

U.S. Food and Drug Administration

Tel: 240-402-8298

[Erica.Giordano@fda.hhs.gov](mailto:Erica.Giordano@fda.hhs.gov)



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."